La Elizabeth M, McGuiness Catherine B, Singer David, Yasuda Marie, Chen Chi-Chang
GSK, Philadelphia, PA, USA.
IQVIA, Wayne, PA, USA.
Hum Vaccin Immunother. 2025 Dec;21(1):2535755. doi: 10.1080/21645515.2025.2535755. Epub 2025 Aug 5.
Older adults and adults with certain chronic conditions are at increased risk for severe respiratory syncytial virus (RSV) disease. In 2023, RSV vaccines first became available in the United States (US) for adults aged ≥60 years. This retrospective database analysis evaluated RSV vaccination uptake from August 2023-February 2025 using IQVIA's open-source pharmacy (LRx) and medical (Dx) claims data. The study included US adults aged ≥60 years with ≥1 claim in 2023. For those without RSV vaccination in 2023, ≥1 claim was also required between January 2024-February 2025. Uptake was assessed as the number and percentage of eligible adults who received an RSV vaccine during the study period. Multivariable logistic regression modeling explored factors associated with RSV vaccination. Nearly 12.8 million adults aged ≥60 years (16.4%) received RSV vaccination between August 2023-February 2025. Uptake generally increased with age and was higher among those with ≥1 potential risk factor for severe RSV disease. Disparities in uptake were observed by race, ethnicity, and other social determinants of health. In multivariable analyses, odds of RSV vaccination were nearly 24 times higher for those who received ≥1 non-RSV vaccine from August 2023-February 2025 versus those who had not. Despite the increased risk of severe RSV disease among older adults and those with certain risk factors, relatively limited RSV vaccination uptake was observed during the 2023-2025 seasons, with disparities observed. Additional efforts are needed to support RSV prevention among those at highest risk and to ensure equitable access to vaccination.
老年人和患有某些慢性病的成年人患严重呼吸道合胞病毒（RSV）疾病的风险增加。2023年，RSV疫苗首次在美国可供60岁及以上的成年人使用。这项回顾性数据库分析使用IQVIA的开源药房（LRx）和医疗（Dx）索赔数据评估了2023年8月至2025年2月期间RSV疫苗的接种情况。该研究纳入了2023年有≥1次索赔记录的60岁及以上美国成年人。对于2023年未接种RSV疫苗的人，2024年1月至2025年2月期间也需要有≥1次索赔记录。接种情况以研究期间接种RSV疫苗的符合条件成年人的数量和百分比来评估。多变量逻辑回归模型探讨了与RSV疫苗接种相关的因素。在2023年8月至2025年2月期间，近1280万60岁及以上的成年人（16.4%）接种了RSV疫苗。接种率一般随年龄增长而增加，在有≥1种严重RSV疾病潜在风险因素的人群中更高。在种族、族裔和其他健康社会决定因素方面观察到了接种差异。在多变量分析中，与未接种的人相比，2023年8月至2025年2月期间接种≥1剂非RSV疫苗的人接种RSV疫苗的几率高出近24倍。尽管老年人和有某些风险因素的人患严重RSV疾病的风险增加，但在2023 - 2025季节期间观察到RSV疫苗接种率相对有限，且存在差异。需要做出更多努力来支持高危人群预防RSV，并确保公平获得疫苗接种。
